The effect of aging on cellular immunity against cancer in SR/CR mice Zheng CuiMark C. Willingham Opinion Paper 17 January 2004 Pages: 473 - 478
Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+ patients with hormone-refractory prostate cancer Satoko MatsuedaKazuhiko KobayashiMamoru Harada Original Article 21 November 2003 Pages: 479 - 489
Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer Michael E. GilloglyNikoletta L. KallinterisJames L. Murray Original Article 22 January 2004 Pages: 490 - 496
A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells Hiroki HayashiRyutaro AsanoToshio Kudo Original Article 25 November 2003 Pages: 497 - 509
Dendritic cells are dysfunctional in patients with operable breast cancer Sukchai SatthapornAdrian RobinsOleg Eremin Original Article 23 January 2004 Pages: 510 - 518
Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies Silvia TanzarellaIlaria LionelloCatia Traversari Original Article 16 January 2004 Pages: 519 - 524
MHC class II and CD80 tumor cell–based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain Dan IlkovitchSuzanne Ostrand-Rosenberg Original Article 17 January 2004 Pages: 525 - 532
Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody Teresa CarterKaty Sterling-LevisPamela J. Russell Original Article 13 January 2004 Pages: 533 - 542
Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines Akihiro TakahashiKoji KonoYoshiro Matsumoto Original Article 10 December 2003 Pages: 543 - 550
Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients Selma UgurelDario UhligUwe Reinhold Original Article 16 January 2004 Pages: 551 - 559
Detection of circulating tumor lysate–reactive CD4+ T cells in melanoma patients Morten LadekarlRalf AggerHans Jørgen G. Gundersen Short Communication 25 February 2004 Pages: 560 - 566